Eternygen

Executive Summary

Eternygen is a Berlin-based biopharmaceutical company founded in 2012, dedicated to developing innovative therapies for aging and dietary-related metabolic diseases. The company's core research focuses on the sodium-coupled citrate transporter (NaCT), a key target for modulating cellular metabolism. Eternygen leverages a network of academic collaborators and contract research organizations to advance its drug discovery pipeline. With the rising prevalence of metabolic disorders such as obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD), Eternygen's approach addresses a significant unmet medical need. The company's platform targets citrate transport, which plays a critical role in lipid and glucose homeostasis, offering potential for disease-modifying treatments. Although still in early stages, Eternygen's science is grounded in well-validated biology, positioning it for future growth.

Upcoming Catalysts (preview)

• Q4 2026Lead Optimization Completion and IND-Enabling Studies40% success
• H1 2027Partnership or Licensing Agreement for NaCT Program30% success
• Q2 2026Publication of Preclinical Efficacy Data in Peer-Reviewed Journal60% success